Not hard to get a patent given the efforts to get through all clinical stages of testing, that’s why it’s not price sensitive. You would expect granting patents to be a given in this space. The success of the trials is what will be price sensitive
Ann: US patent allowed for CHM 0201 (CORE-NK) technology, page-7
Add CHM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
1.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $9.951M | |||
| Open | High | Low | Value | Volume |
| 1.1¢ | 1.2¢ | 1.0¢ | $38.54K | 3.639M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 9 | 2646760 | 1.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.1¢ | 729690 | 4 |
View Market Depth
| Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
| CHM (ASX) Chart |